Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15966070 | 0.90 | HPGD (0.64) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL11087644 | 0.90 | NPC1 (0.63) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL11087638 | 0.83 | NPC1 (0.60) | SMN1; SMN2NPC1RAB9AKMT2AKCNA5 | |
| SCHEMBL3331311 | 0.83 | HPGD (0.60) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL24142285 | 0.82 | KCNA5 (0.60) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL10269523 | 0.82 | KMT2A (0.58) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL2210472 | 0.82 | HPGD (0.62) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL4240788 | 0.82 | KCNA5 (0.57) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL461599 | 0.81 | HPGD (0.64) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL5221046 | 0.81 | HPGD (0.64) | HPGDSMN1; SMN2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262693-A1 | METHOTREXATE ANALOGS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8093227-B2 | Monosaccharide compounds and methods therefor | ALCHEMIA PTY LTD (AU) | 2012-01-10 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | ALCHEMIA PTY LTD. (AU) | 2010-07-22 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7417129-B2 | Combinatorial libraries of monosaccharides | ALCHEMIA PTY LTD (AU) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | SLC5A1, UGGT1, MRPL21 | HPGD 3034/4885SMN1; SMN2 3629/4885NPC1 969/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | HPGD 1224/4885SMN1; SMN2 3213/4885NPC1 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.